Delisting risk
Lite Strategy (LITS)
Manages a Litecoin reserve strategy while retaining two pre-clinical oncology drug assets.
$1.01
Pre-market−0.03 (−3.35%)
At close$1.05(+5.13%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions39 holders · as of Mar 31, 2026 | 17.31% | 5.89M shares | |
| Insiders2 holders · as of Jun 25, 2026 | 11.17% | 3.80M shares | |
| Otherremainder | 71.52% | 24.34M shares |
34.03M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
39 holders · 5.89M shares · 10 new positions · 13 increased · 8 reduced · 14 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Renaissance Technologies LLC | 1.74M | 5.13% | +203.3K | May 14, 2026 |
| Vanguard Capital Management LLC | 1.04M | 3.07% | +1.04Mnew | May 15, 2026 |
| Citadel Advisors LLC | 730.1K | 2.15% | −648.2K | May 15, 2026 |
| Two Sigma Investments, LP | 614.4K | 1.81% | −43.2K | May 15, 2026 |
| Geode Capital Management, LLC | 401.1K | 1.18% | +69.7K | May 15, 2026 |
| Marshall Wace, LLP | 333.5K | 0.98% | −425.9K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 194.0K | 0.57% | +194.0Knew | May 8, 2026 |
| BlackRock, Inc. | 157.9K | 0.46% | 0 | May 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Citadel Advisors LLC | 9.75% | 3.17M | 13G | Jul 29, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 24, 2026 | James P. Flynndirector | Purchase | 25,000 | $0.8555 | 125,000 |
| Dec 19, 2025 | James P. Flynndirector | Purchase | 70,000 | $1.40 | 100,000 |
| Dec 18, 2025 | Alexander Schornstein10 percent owner | Sale | 690,611 | $1.37 | 3,674,862 |
| Nov 19, 2025 | James P. Flynndirector | Purchase | 12,100 | $1.88 | 30,000 |
CongressHouse and Senate disclosures
Not reported.